BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 94 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 1.49 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20 | -90.3% | 100 | 0.0% | 0.00% | – |
| Q2 2023 | $206 | -37.6% | 100 | 0.0% | 0.00% | – |
| Q1 2023 | $330 | +101.2% | 100 | 0.0% | 0.00% | – |
| Q4 2022 | $164 | – | 100 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q1 2022 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q4 2021 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q3 2021 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q2 2021 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q1 2021 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q4 2020 | $0 | -100.0% | 100 | 0.0% | 0.00% | -100.0% |
| Q3 2020 | $2,000 | +100.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $1,000 | – | 100 | 0.0% | 0.00% | – |
| Q1 2020 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q4 2019 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q3 2019 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q2 2019 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q1 2019 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q4 2018 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q3 2018 | $0 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Weaver Consulting Group | 130,000 | $437,000 | 0.21% |
| Ikarian Capital, LLC | 304,161 | $1,022,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 265,000 | $890,000 | 0.12% |
| S.C. Financial Services, Inc. | 15,285 | $51,000 | 0.06% |
| JMAC ENTERPRISES LLC | 45,430 | $153,000 | 0.04% |
| CFO4Life Group, LLC | 12,000 | $40,000 | 0.01% |
| OSAIC HOLDINGS, INC. | 10,839 | $1,329,000 | 0.00% |
| INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC | 3,000 | $10,000 | 0.00% |
| BOOTHBAY FUND MANAGEMENT, LLC | 29,186 | $98,000 | 0.00% |
| RAYMOND JAMES & ASSOCIATES | 190,403 | $640,000 | 0.00% |